Patch-free Occlusion Therapy
Study Details
Study Description
Brief Summary
The purpose of the study is to determine whether a patch-free occlusion therapy leads to better visual outcomes in young children with amblyopia than standard-of-care occlusion therapy with an adhesive patch and whether this is associated with better adherence to the treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This is a single-site randomized clinical trial to compare patch-free occlusion therapy with standard-of-care occlusion therapy with an adhesive patch in young children with amblyopia. Participants will be referred from local pediatric ophthalmologists. Following informed consent, children will complete baseline testing to confirm eligibility and provide pre-treatment measurements of visual acuity, suppression, stereoacuity, motor skills, self-perception, and quality of life. Eligible children will then be randomly allocated to either patch-free occlusion therapy or standard-of-care occlusion therapy with an adhesive patch.
Children will participate in their assigned occlusion therapy at home for 12 weeks (primary outcome). Adherence will be objectively monitored with a Theramon sensor. Vision will be re-assessed at 6 weeks and all tests will be repeated at 12 weeks. The patch-free occlusion group will have an option to continue the patch-free occlusion for and additional 6 or 12 weeks (24 weeks total). The standard-of-care occlusion group will be offered the opportunity to use the patch-free treatment at the 12 week visit through 24 weeks. Children who choose to remain in the study beyond the 12 week primary outcome visit will have vision reassessed at 18 and 24 weeks.
The primary analysis will be a comparison of improvement in amblyopic eye visual acuity (baseline-12 weeks) between the patch-free occlusion group and the standard-of-care patching group. Secondary analyses will include comparisons adherence to each treatment, comparison of the proportion of children in each group with visual acuity ≤0.1 logMAR (recovered) at 6 and 12 weeks visit and 95% CIs (at 6 and 12 weeks), comparisons of changes in extent of suppression, depth of suppression, stereoacuity, motor skills standard scores, self-perception scores, and PedEyeQ domain scores. Associations among hours of treatment, changes in visual acuity, suppression, and stereoacuity, will be explored and modeled for dose-response relationships. In exploratory analyses, we will examine whether there are additional improvements in visual acuity, suppression, or stereoacuity between 12 and 24 weeks for the patch-free group (12, 18, and 24 weeks means and 95% CIs).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Patch-free occlusion therapy
|
Device: Patch-free occlusion therapy
Use of filters in glasses to provide occlusion therapy
|
| Active Comparator: Standard-of-care patching with an adhesive patch
|
Device: Adhesive patch
Standard-of-care occlusion therapy with an adhesive patch
|
Outcome Measures
Primary Outcome Measures
- Change in amblyopic eye visual acuity measured with a logMAR visual acuity chart [12 weeks]
change in logMAR relative to baseline
Secondary Outcome Measures
- Change in amblyopic eye visual acuity measured with a logMAR visual acuity chart [6,18, and 24 weeks]
change in logMAR relative to baseline
- Adherence to patching or viewing videos with glasses measured with a sensor [6 and 12 weeks]
cumulative hours of treatment with the patch or glasses used to watch videos objectively monitored with the skin temperature sensitive Theramon sensor
- Proportion of children who have recovered [6 and 12 weeks]
Proportion of children who attain amblyopic eye visual acuity of 0.1 logMAR or better
- Change in extent of suppression assessed with W4 test [6 and 12 weeks]
changes in log deg measure with W4 test
- change in stereoacuity assessed with the Randot Preschool Stereoacuity Test [6 and 12 weeks]
change in log arcsec
- Change in motor skills assessed with the Movement Assessment Battery for Children-2 [12 weeks]
change in Movement Assessment Battery for Children-2 (MABC-2) standard scores relative to baseline (normed and scaled 0-19 for worst to best, with 10=average, 5-6 = "at risk", and <5 = "significant impairment")
- Change in self-perception assessed with the Pictorial Scale of Perceived Competence and Social Acceptance for Young Children [12 weeks]
change in domain scores of the Pictorial Scale of Perceived Competence and Social Acceptance for Young Children (standard scores scaled to range from 0 to 100 for worst to best)
- Improvement in quality of life assesses with the Pediatric Eye Questionnaire [12 weeks]
change in domain scores of the Pediatric Eye Questionnaire (PedEyeQ; Rasch-calibrated and scaled to score from 0 to 100 for worst to best)
- Change in depth of suppression assessed with the contrast balance index [6 and 12 weeks]
change in contrast balance index (ratio of amblyopic eye to fellow eye contrast needed to overcome suppression
Eligibility Criteria
Criteria
Inclusion Criteria:
-
3-7 years
-
male and female
-
strabismic, anisometropic, or combined mechanism amblyopia (visual acuity: 0.3-0.8 logMAR)
-
interocular visual acuity difference ≥0.3 logMAR
-
wearing glasses (if needed) for a minimum of 8 weeks with no change in visual acuity at 2 visits ≥4 weeks apart
-
child's ophthalmologist and family willing to forgo standard patching treatment during the study
Exclusion Criteria:
-
Prematurity ≥8 wk
-
coexisting ocular or systemic disease
-
developmental delay
-
myopia > -3.00D
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Retina Foundation of the Southwest
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RFSW113A